An Efficient Low Cost Method for Gene Transfer to T Lymphocytes

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Chicaybam, Leonardo ^a,b   Sodre, Andressa Laino ^a   Curzio, Bianca Azevedo ^a   Bonamino, Martin Hernan ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL EXPANSION; CELL VIABILITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLYSIS; DNA MODIFICATION; ELECTROPORATION; ELECTROPORATION DEVICE; GAIN OF FUNCTION MUTATION; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MEDICAL DEVICE; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; STABLE EXPRESSION; T LYMPHOCYTE; TRANSIENT EXPRESSION;

ANIMALS; CELLS, CULTURED; ELECTROPORATION; GENE TRANSFER TECHNIQUES; HUMANS; MICE; T-LYMPHOCYTES;

LENTIVIRUS; MURINAE;

EID: 84875426738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060298     Document Type: Article

References (48)

1. Ebert O, Finke S, Salahi A, Herrmann M, Trojaneck B, et al. (1997) Lymphocyte apoptosis: induction by gene transfer techniques. Gene therapy 4: 296-302.
2. Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, et al. (2000) High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392-3398.
3. Serafini M, Bonamino M, Golay J, Introna M, (2004) Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis. haematologica 89: 86-95.
4. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, et al. (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nature Biotechnology 24: 687-696 doi:10.1038/nbt1216.
5. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science 326: 818-823 doi:10.1126/science.1171242.
6. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
7. Bonamino M, Serafini M, D'Amico G, Gaipa G, Todisco E, et al. (2004) Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. Gene Therapy 11: 85-93 doi:10.1038/sj.gt.3302141.
8. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine 365: 1673-1683.
9. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine 14: 1264-1270 doi:10.1038/nm.1882.
10. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine 3: 95ra73-95ra73 doi:10.1126/scitranslmed.3002842.
11. Porter DL, Levine BL, Kalos M, Bagg A, June CH, (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine 365: 725-733.
12. Brenner MK (2012) Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Therapy. Available: http://www.nature.com/doifinder/10.1038/cgt.2012.74.Accessed 17 October 2012.
13. Apollonio F, Liberti M, Marracino P, Mir L (2012) Electroporation mechanism: Review of molecular models based on computer simulation. Antennas and Propagation (EUCAP), 2012 6th European Conference on. pp. 356-358. Available: http://ieeexplore.ieee.org/xpls/abs_all.jsp?arnumber=6206719. Accessed 26 September 2012.
14. Kotnik T, Kramar P, Pucihar G, Miklavcic D, Tarek M, (2012) Cell membrane electroporation-Part 1: The phenomenon. Electrical Insulation Magazine, IEEE 28: 14-23.
15. Murakami T, Sunada Y, others (2011) Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances. Current gene therapy 11. Available: http://ukpmc.ac.uk/abstract/MED/22023474. Accessed 26 September 2012.
16. Van Tendeloo VFI, Ponsaerts P, Lardon F, Nijs G, Lenjou M, et al. (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98: 49-56.
17. Bell MP, Huntoon CJ, Graham D, McKean DJ, (2001) The analysis of costimulatory receptor signaling cascades in normal T lymphocytes using in vitro gene transfer and reporter gene analysis. Nat Med 7: 1155-1158 doi:10.1038/nm1001-1155.
18. Zhao Y, Zheng Z, Cohen C, Gattinoni L, Palmer D, et al. (2006) High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Molecular Therapy 13: 151-159 doi:10.1016/j.ymthe.2005.07.688.
19. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, et al. (2013) Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood.Journal of Visualized Experiments. Available: http://www.jove.com/video/50070/clinical-application-sleeping-beauty-artificial-antigen-presenting. Accessed 21 February 2013.
20. Hackett PB, Largaespada DA, Cooper LJ, (2010) A Transposon and Transposase System for Human Application. Molecular Therapy 18: 674-683 doi:10.1038/mt.2010.2.
21. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, et al. (2012) Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. Human Gene Therapy 23: 444-450 doi:10.1089/hum.2011.167.
22. Huang X, Guo H, Tammana S, Jung Y-C, Mellgren E, et al. (2010) Gene Transfer Efficiency and Genome-Wide Integration Profiling of Sleeping Beauty, Tol2, and PiggyBac Transposons in Human Primary T Cells. Molecular Therapy 18: 1803-1813 doi:10.1038/mt.2010.141.
23. Restifo NP, Dudley ME, Rosenberg SA, (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 12: 269-281 doi:10.1038/nri3191.
24. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, et al. (2011) Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research 17: 4550-4557 doi:10.1158/1078-0432.CCR-11-0116.
25. Rosenberg SA, Dudley ME, (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology 21: 233-240 doi:10.1016/j.coi.2009.03.002.
26. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, et al. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116: 4099-4102 doi:10.1182/blood-2010-04-281931.
27. Chicaybam L, Laino Sodré A, Bonamino M, (2011) Chimeric Antigen Receptors in Cancer Immuno-Gene Therapy: Current Status and Future Directions. International Reviews of Immunology 30: 294-311 doi:10.3109/08830185.2011.595855.
28. Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, et al. (2012) Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. Science Translational Medicine 4: 132ra53-132ra53 doi:10.1126/scitranslmed.3003761.
29. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, et al. (2008) Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System. Cancer Res 68: 2961-2971 doi:10.1158/0008-5472.CAN-07-5600.
30. Jin Z, Maiti S, Huls H, Singh H, Olivares S, et al. (2011) The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Therapy 18: 849-856 doi:10.1038/gt.2011.40.
31. Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, et al. (2009) Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Therapy 16: 1042-1049 doi:10.1038/gt.2009.54.
32. D'Amico G, Bonamino M, Dander E, Marin V, Basso G, et al. (2006) T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia 20: 2015-2024.
33. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui C-H, et al. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-684 doi:10.1038/sj.leu.2403302.
34. Flanagan M, Gimble JM, Yu G, Wu X, Xia X, et al. (2011) Competitive electroporation formulation for cell therapy. Cancer gene therapy 18: 579-586.
35. Sutlu T, Nyström S, Gilljam M, Stellan B, Applequist SE, et al. (2012) Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy. Human Gene Therapy 23: 1090-1100 doi:10.1089/hum.2012.080.
36. Grund EM, Muise-Helmericks RC, (2005) Cost efficient and effective gene transfer into the human natural killer cell line, NK92. Journal of Immunological Methods 296: 31-36 doi:10.1016/j.jim.2004.10.008.
37. Imai C, (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383 doi:10.1182/blood-2004-12-4797.
38. Tran J, Kung SK, (2007) Lentiviral Vectors Mediate Stable and Efficient Gene Delivery into Primary Murine Natural Killer Cells. Molecular Therapy 15: 1331-1339 doi:10.1038/sj.mt.6300184.
39. Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, et al. (2008) Resistance of mature T cells to oncogene transformation. Blood 112: 2278-2286 doi:10.1182/blood-2007-12-128751.
40. Westwood JA, Murray WK, Trivett M, Shin A, Neeson P, et al. (2008) Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Therapy 15: 1056-1066 doi:10.1038/gt.2008.47.
41. Geurts A, (2003) Gene transfer into genomes of human cells by the sleeping beauty transposon system. Molecular Therapy 8: 108-117 doi:10.1016/S1525-0016(03)00099-6.
42. Galla M, Schambach A, Falk CS, Maetzig T, Kuehle J, et al. (2011) Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Research 39: 7147-7160 doi:10.1093/nar/gkr384.
43. Lehner M, Götz G, Proff J, Schaft N, Dörrie J, et al. (2012) Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection. PLoS ONE 7: e31210 doi:10.1371/journal.pone.0031210.
44. Mitchell DA, Karikari I, Cui X, Xie W, Schmittling R, et al. (2008) Selective Modification of Antigen-Specific T Cells by RNA Electroporation. Human Gene Therapy 19: 511-521 doi:10.1089/hum.2007.115.
45. Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman JL, Budak-Alpdogan T, et al. (2009) Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Human gene therapy 20: 51-61.
46. Schaft N, Dörrie J, Müller I, Beck V, Baumann S, et al. (2005) A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunology, Immunotherapy 55: 1132-1141 doi:10.1007/s00262-005-0098-2.
47. Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VFI, Berneman ZN, (2005) Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol 43: 213-216.
48. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, et al. (2011) Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Research 71: 3516-3527 doi:10.1158/0008-5472.CAN-10-3843.